Critical illness polyneuropathy: a rare but serious adverse event in pediatric oncology

Jorma Charisius1, Martina Stiefel, Nick Merkel

  • 1University Children's Hospital, University Medical Center, Martin-Luther University Halle-Wittenberg, Halle, Germany.

Pediatric Blood & Cancer
|September 18, 2009
PubMed

Insights

Critical illness polyneuropathy (CIP) can worsen sepsis in pediatric cancer patients, causing weakness and breathing difficulties. This case highlights CIP in an adolescent with T-cell leukemia following sepsis and mechanical ventilation.

Area of Science:

  • Pediatric Neurology
  • Oncology
  • Critical Care Medicine

Background:

  • Critical illness polyneuropathy (CIP) is a serious complication in critically ill patients, particularly those with sepsis and multiorgan dysfunction.
  • Pediatric oncology patients with acute leukemia are susceptible to neurological complications, including CIP, which can manifest as quadriparesis and prolonged mechanical ventilation dependence.

Observation:

  • This report details an adolescent with T-cell acute lymphoblastic leukemia who developed CIP after sepsis requiring mechanical ventilation and catecholamine support.
  • The patient presented with quadriparesis and significant challenges in weaning from mechanical ventilation, indicative of severe neuromuscular compromise.

Findings:

  • The clinical presentation of quadriparesis and difficult weaning strongly suggested CIP in the context of sepsis and underlying leukemia.
  • Differential diagnoses considered included vincristine-induced polyneuropathy, anterior lumbosacral radiculopathy (ALR), Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, all relevant in pediatric leukemia patients.

Implications:

  • Early recognition and diagnosis of CIP are crucial for appropriate management in pediatric oncology patients with sepsis.
  • Understanding the differential diagnoses aids in distinguishing CIP from other neuropathies, guiding treatment strategies and improving patient outcomes.
  • This case underscores the importance of considering CIP in pediatric cancer patients experiencing unexplained neuromuscular weakness during critical illness.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...